


CLAIMS


Claim 1 (previously presented): A triptolide derivative of formula I




I

wherein R1 is [[H,]] phosphate ($-\text{P}(\text{O})(\text{OR}_1)_2$), or phosphite ($-\text{P}(\text{H})(\text{OR}_1)_2$), and
X₁ and X₂ are Na, K, or NH₄.

Claim 2 (currently amended): A method for preparation of the compound according to claim 1, comprising the step of reacting the first lead compound triptolide with X, X being POCl₃, PCl₃ or other phosphonate halide, phosphate, phosphite halide, phosphite as shown by the following formula:




Claim 3 (currently amended): A triptolide derivative of formula II




II

wherein R_1 is alkyl having 1-4 carbon atom(s), $-C(=O)(CH_2)_nCO_2-$, or $C(=O)(CH_2)_nCO_2H$, wherein n is an integer of 1-4, or phosphate ($\text{P}(\text{O})(\text{O}X_1)(\text{O}X_2)$), or phosphite ($\text{P}(\text{H})(\text{O}X_1)(\text{O}X_2)$), wherein X_1 and X_2 are Na, K, or NH_4 ; and wherein R_2 is H, $-SCN$, $-Cl$ or $-Br$.

Claim 4 (currently amended): A method for ~~preparation of~~ preparing the compound according to claim 3, comprising the step of esterifying the a second lead compound 12- β -thiocyano-13- α -hydroxy triptolide with Y, Y being succinic anhydride to obtain the compound of formula II as shown by the following formula:




Claim 5 (previously presented): A triptolide derivative of formula IIIa



IIIa

wherein R₂ is H, SCN, Cl or Br.

Claim 6 (currently amended): A method ~~for preparation of~~ of preparing the compound according to claim 5, comprising the step of reacting the second lead compound 12-β-thiocyano-13-α-hydroxy triptolide with Z, Z being POCl₃ or other phosphonate halide, phosphate, phosphite and the like as shown by the following formula:



Claim 7 (Currently amended): ~~The compound of claim 5 wherein said compound is used in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent~~ A method for treatment of prevention of inflammatory diseases, comprising administrating the compounds according to claim 5 to a subject.


Claim 8 (Canceled)

Claim 9 (Canceled)

Claim 10 (Currently amended): The use method according to claim 9 7, wherein ~~said diseases are selected from the group consisted of rheumatoid~~ wherein the inflammatory disease is arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.

Claim 11 (currently amended): ~~The use according to claim 7, wherein said immunosuppressive agent or anti-inflammatory agent is used in the~~ A method for prevention of organ rejection and prolongation of the survival time of transplanted organ in organ transplantation comprising administrating the compounds according to claim 5 to a subject.


Claim 12 (previously presented): A triptolide derivative of formula IIIb




IIIb

wherein R₂ is H, SCN, Cl or Br.

Claim 13 (Currently amended): A method ~~for preparation of~~ of preparing the compound according to claim 12, comprising the step of reacting the second lead compound 12- β -thiocyano-13- α -hydroxy triptolide with Z, Z being POCl₃ or other phosphonate halide, phosphate, phosphite and the like as shown by the following formula:



, or the step of reacting the first lead compound triptolide with Z, Z being POCl₃ or other phosphonate halide, phosphite halide and the like as shown by the following formula:



Claim 14 (Currently amended): ~~The compound of claim 12 wherein said compound is used in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent~~ A method for treatment or prevention of inflammatory diseases, comprising administrating the compounds according to claim 12 to a subject.

Claim 15 (Canceled)

Claim 16 (Canceled)

Claim 17 (Currently amended): The use method according to claim 14, wherein ~~said diseases are selected from the group consisted of rheumatoid~~ wherein the inflammatory disease is arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.

Claim 18 (new): ~~The use according to claim 14, wherein said immunosuppressive agent or anti-inflammatory agent is used in the A method for prevention of organ rejection and prolongation of the survival time of transplanted organ in organ transplantation comprising administrating the compounds according to claim 12 to a subject.~~

Claim 19 (currently amended): ~~The compound of claim 3 wherein said compound is used in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent A method for treatment of prevention of inflammatory diseases, comprising administrating the compounds according to claim 3 to a subject.~~

Claim 20 (Canceled)

Claim 21 (Canceled)

Claim 22 (new): The use method according to claim 19, wherein ~~said diseases are selected from the group consisted of rheumatoid~~ wherein the inflammatory disease is arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.


Claim 23 (new): ~~The use according to claim 19, wherein said immunosuppressive agent or anti-inflammatory agent is used in the A method for prevention of organ rejection and prolongation of the survival time of transplanted organ in organ transplantation comprising administrating the compounds according to claim 3 to a subject.~~

Claim 24 (Canceled)

Claim 25 (Canceled)

Claim 26 (Canceled)**Claim 27 (Canceled)****Claim 28 (Canceled)**

Claim 29 (Currently amended): ~~The compound according to Claim 3~~ A triptolide derivative of formula II



II

wherein R₁ is one of a

phosphate ($-\overset{\text{O}}{\underset{\text{O}}{\text{P}}}(\text{O}^{\text{X}_1})_2$) or a phosphite ($-\overset{\text{O}}{\underset{\text{H}}{\text{P}}}(\text{O}^{\text{X}_1})_2$) and wherein X₁ and X₂

are Na or K or NH₄ and R₂ is H or SCN or Cl or Br.


Claim 30 (Currently amended): ~~The compound of claim 29 wherein said compound is used in the preparation of medicament as immunosuppressive agent or anti-inflammatory agent~~ A method for treatment of prevention of inflammatory diseases, comprising administering the compounds according to claim 29 to a subject.

Claim 31 (Canceled)**Claim 32 (Canceled)**

Claim 33 (Currently amended): The use method according to claim 32 30, wherein said ~~diseases are selected from the group consisted of rheumatoid~~ wherein the inflammatory disease is arthritis, asthma, systemic lupus erythematosus, psoriasis, multiple sclerosis, atherosclerosis, type I diabetes, and nephritis.

Claim 34 (Currently amended): The use according to claim 30, wherein said ~~immunosuppressive agent or anti-inflammatory agent is used in the A method for prevention of organ rejection and prolongation of the survival time of transplanted organ in organ transplantation~~ comprising administering the compounds according to claim 29 to a subject.

Claim 35 (currently amended): A method ~~for preparation of~~ of preparing of the compound according to claim 5, comprising the step of reacting the first lead compound triptolide with Z, Z being POCl₃, or other phosphonate halide, phosphate halide and the like as shown by the following formula:



Claim 36 (new) : A method ~~for preparation of~~ of preparing the compound according to claim 3, comprising the step of phosphoric esterifying the second lead compound 12- β -thiocyano-13- α -hydroxy triptolide with X, X being POCl₃, PCl₃, phosphonate halide, phosphate, phosphite halide, or phosphate to obtain the compound of formula II as shown by the following formula:

